Investigational drug · Phase 2
ABSK-011
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Feb 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "ABSK-011"
First trial start
2021
Dec 30, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABSK-011", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma (HCC)
- Hepatocellular Carcinoma
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ABSK-011" as an intervention, largest first.
Abbisko Therapeutics Co, LtdIndustry
NCT04906434 · 200 participants (planned) · Start Feb 26, 2020 · Primary completion Dec 31, 2027
Drug: ABSK-011 · For: Advanced Liver Cancer
Sites: Phoenix, Arizona; Jacksonville, Florida; Tampa, Florida · 32 sites in all
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionPivotal-lookingRecruiting
Abbisko Therapeutics Co, LtdIndustry
NCT07327034 · 141 participants (planned) · Start Jun 13, 2025 · Primary completion Jun 30, 2027
Drug: ABSK-011+BSC; Placebo+BSC · For: Hepatocellular Carcinoma (HCC)
Sites: Hefei, China; Beijing, China; Chongqing, China · 51 sites in all
- A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC PatientsPivotal-lookingEnrolling by invitation
Abbisko Therapeutics Co, LtdIndustry
NCT05441475 · 118 participants (planned) · Start Dec 30, 2021 · Primary completion Dec 31, 2028
Drug: ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w; ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg and 1 more · For: Hepatocellular Carcinoma
Sites: Hubei, China
RenJi HospitalAcademic, hospital or other
NCT06978933 · 42 participants (planned) · Start Apr 30, 2025 · Primary completion Dec 2026
Drug: ABSK-011 · For: HCC - Hepatocellular Carcinoma
Sites: Shanghai, China
Abbisko Therapeutics Co, LtdIndustry
NCT06306872 · 40 participants · Start Feb 23, 2024 · Primary completion Sep 30, 2025
Drug: Sequence A ABSK-011; Sequence B ABSK-011 · For: Healthy Subjects
Sites: Wuxi, China
Asan Medical CenterAcademic, hospital or other
NCT07010497 · 33 participants (planned) · Start Mar 16, 2026 · Primary completion Mar 31, 2029
Drug: irpagratinib · For: Carcinoma, Hepatocellular
Sites: Seoul, South Korea · 3 sites in all
Abbisko Therapeutics Co, LtdIndustry
NCT07700953 · 30 participants (planned) · Start Jul 21, 2026 · Primary completion Aug 10, 2026
Drug: ABSK-011 Capsules; omeprazole enteric-coated tablets · For: Healthy Participants
Sites: Wuxi, China
- A Mass Balance Study of [14C]ABSK011Not yet recruiting
Abbisko Therapeutics Co, LtdIndustry
NCT06896760 · 6 participants (planned) · Start Apr 7, 2025 · Primary completion Nov 7, 2025
Drug: [14C]ABSK011 · For: Healthy Subjects
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma.
Zhan TA, Xia F, Huang HW, et al. · World J Gastrointest Oncol 2025
- Improvements in advanced hepatocellular carcinoma to repeat implementation of primary protocol after cancer progression occurs following sequential systemic therapy and a clinical trial: A case report.
Huang H, Wei Q, Leng C, et al. · Medicine (Baltimore) 2024
Also in development for Hepatocellular Carcinoma (HCC)
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- CobolimabPhase 32 trials
GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma
- IBI310Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma
- TPST-1120Phase 32 trials
Roche (Genentech) · Advanced Liver Cancers, Hepatocellular Carcinoma (HCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.